What is the 13F Pro Quality Score for SIBN?

13F Pro ranks SI-BONE, Inc. (SIBN) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View SIBN's current score at https://13fpro.ai/research/SIBN (free sign-up required for the full ranking).

Where does 13F Pro source SIBN data?

All SI-BONE, Inc. fundamentals and ownership data come directly from SEC EDGAR. SI-BONE, Inc. files with the SEC under CIK 1459839. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is SIBN in?

SI-BONE, Inc. (SIBN) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is SIBN research updated on 13F Pro?

SIBN's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

SI-BONE, Inc.(SIBN)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1459839 SIBN stock profile & AI dashboard →

13F Pro Quality Score

37.7/100

Rank #2,046 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

80.5/100

Profitability

26.9/100

Balance Sheet

18.7/100

Earnings Quality

30.0/100

Free Cash Flow

22.0/100

Institutional Flow

85.9/100

Revenue Scale

24.1/100

Dilution Risk

14.2/100

SIBN Stock Analysis & AI Quality Score

AI stock analysis and institutional research for SI-BONE, Inc. (SIBN), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SIBN at 37.7/100 on a 32-signal composite quality model, placing it at rank #2,046 of 2,879 stocks — the bottom half of the AI-ranked universe. SIBN scores in the top quartile across institutional flow (85.9), revenue growth (80.5). Areas of concern include balance sheet strength (18.7) and free cash flow (22.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 14.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), SI-BONE, Inc. reports quarterly revenue of $52.6M, net income of $-4.3M, an operating margin of -9.7%. Top institutional holders of SIBN by reported 13-F value include First Light Asset Management,, BlackRock,, AMERICAN CENTURY COMPANIES, based on the most recent SEC filings. SIBN trades on the Nasdaq exchange and files with the SEC under CIK 1459839. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SIBN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for SI-BONE, Inc. directly from SEC EDGAR. SI-BONE, Inc.'s 13F Pro composite quality score has ranged between 8 and 66 since 2021, currently 37.7 — an improving long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about SI-BONE, Inc.

Quirks, history, and lore behind SIBN — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. medical device company · small-cap · listed on Nasdaq · headquartered in California.
2
The Numbers
Annual revenue in the range of $150–200 million — not a giant, but growing steadily in a niche market that most people have never heard of.
3
The History
Founded in the early 2000s, the company spent years building clinical evidence before earning FDA clearance for its minimally invasive implant system.
4
The Secret
It focuses entirely on one very specific joint in the body: the sacroiliac joint, which sits at the base of the spine where it meets the pelvis — a common but underdiagnosed source of chronic low back pain.
5
The Lore
Its flagship implants are small titanium triangular devices hammered across the SI joint to fuse it, and the company has trained thousands of spine and orthopedic surgeons to perform the procedure.
6
The Giveaway
The company name is literally a hyphenated abbreviation of the joint it treats — the sacroiliac bone — making it arguably the most on-the-nose medical device brand on the market.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$52.6M

Net Income

Q1 2026

$-4.3M

Free Cash Flow

Q1 2026

$-3.4M

Operating Margin

Q1 2026

-9.7%

D/E Ratio

Q1 2026

0.20

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+20.2% YoY

$200.9MFY 2025

FY22 $106.4MFY23 $138.9MFY24 $167.2MFY25 $200.9M

Net Income

+38.8% YoY

$-18.9MFY 2025

FY22 $-61.3MFY23 $-43.3MFY24 $-30.9MFY25 $-18.9M

Operating Income

+36.6% YoY

$-22.3MFY 2025

FY22 $-59.6MFY23 $-46.9MFY24 $-35.2MFY25 $-22.3M

EPS (Diluted)

+41.3% YoY

$-0.44FY 2025

FY22 $-1.79FY23 $-1.13FY24 $-0.75FY25 $-0.44

Total Assets

+3.5% YoY

$238.6MFY 2025

FY22 $157.6MFY23 $230.4MFY24 $230.4MFY25 $238.6M

Total Debt

+0.3% YoY

$35.6MFY 2025

FY22 $35.2MFY23 $36.1MFY24 $35.5MFY25 $35.6M

Op. Cash Flow

+94.6% YoY

$-675.0KFY 2025

FY22 $-41.7MFY23 $-18.7MFY24 $-12.4MFY25 $-675.0K

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2020	FY 2019
Revenue	$200.9M +20.2%	$167.2M +20.4%	$138.9M +30.5%	$106.4M +45.0%	$73.4M +9.0%	$67.3M
Net Income	$-18.9M +38.8%	$-30.9M +28.7%	$-43.3M +29.3%	$-61.3M -40.3%	$-43.7M -13.8%	$-38.4M
Operating Income	$-22.3M +36.6%	$-35.2M +24.9%	$-46.9M +21.3%	$-59.6M -54.6%	$-38.6M -7.1%	$-36.0M
EPS (Diluted)	$-0.44 +41.3%	$-0.75 +33.6%	$-1.13 +36.9%	$-1.79 -19.3%	$-1.50	—
Total Assets	$238.6M +3.5%	$230.4M +0.0%	$230.4M +46.3%	$157.6M -29.4%	$223.1M +90.7%	$117.0M
Total Debt	$35.6M +0.3%	$35.5M -1.7%	$36.1M +2.5%	$35.2M -10.9%	$39.5M -9.5%	$43.6M
Operating Cash Flow	$-675.0K +94.6%	$-12.4M +33.6%	$-18.7M +55.1%	$-41.7M -35.9%	$-30.7M +3.1%	$-31.6M

AI Insight: SIBN Financial Trends

SI-BONE is narrowing losses steadily — Q4 2025 operating loss compressed to -$2M from -$10M in Q2 2024 — but profitability remains elusive.

• Operating loss shrank from -$10M in Q2 2024 to -$2M in Q4 2025, the best result in the observed period.

• Revenue grew from $40M in Q2 2024 to $56M in Q4 2025, a 40% increase over six quarters.

• Operating cash flow improved from -$6M in Q2 2024 to +$2M in Q4 2025, though Q1 2026 slipped back to -$2M.

• Equity steadily expanded from $165M in Q2 2024 to $179M in Q1 2026, with total debt stable near $36M.

⚠ Q1 seasonality is notable: operating loss widened to -$5M in Q1 2026 vs. -$2M in Q4 2025, reversing recent momentum.

⚠ Net income remains negative across all eight quarters; the path to GAAP profitability is still unconfirmed.

⚠ Total debt has not declined, holding at $36M in Q1 2026; leverage reduction would signal financial strengthening.

AI Insight: SIBN Ratio Trends

SIBN's operating losses have narrowed sharply from -25.2% in Q2 2024 to -9.7% in Q1 2026, signaling meaningful but still-incomplete progress toward profitability.

• Operating margin improved from -25.2% in Q2 2024 to -4.4% in Q4 2025, the best single quarter in the dataset.

• Net profit margin followed the same path, narrowing from -22.4% in Q2 2024 to -2.9% in Q4 2025.

• Leverage is stable and declining slightly; D/E edged from 0.22 in Q2–Q3 2024 to 0.20 in Q4 2025 and Q1 2026.

• All return metrics — ROE, ROA, ROIC — remain negative across every reported period, indicating no positive economic returns yet.

⚠ Q1 2026 operating margin deteriorated to -9.7% from Q4 2025's -4.4%, raising questions about seasonal durability of improvement.

⚠ ROIC of -9.3% in Q1 2026 versus -4.6% in Q4 2025 suggests the path to positive capital returns remains uneven.

⚠ Whether Q4 2025 margin strength recurs in future Q4 periods will signal whether SIBN is structurally approaching breakeven.

Get alerted when SIBN's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for SI-BONE, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of SIBN

First Light Asset Management, LLC
$67.6M5,353,190 sh
BlackRock, Inc.
$43.3M3,428,541 sh
AMERICAN CENTURY COMPANIES INC
$31.7M2,509,065 sh
BROWN ADVISORY INC
$26.8M2,122,332 sh
CADIAN CAPITAL MANAGEMENT, LP
$23.8M1,887,472 sh
VANGUARD CAPITAL MANAGEMENT LLC
$22.3M1,764,313 sh
Granahan Investment Management, LLC
$22.0M1,739,097 sh
Impax Asset Management Group plc
$18.0M1,425,010 sh
Nuveen, LLC
$16.2M1,285,511 sh
SILVERCREST ASSET MANAGEMENT GROUP LLC
$15.7M1,244,584 sh

Fund	Value	Shares
First Light Asset Management, LLC	$67.6M	5,353,190
BlackRock, Inc.	$43.3M	3,428,541
AMERICAN CENTURY COMPANIES INC	$31.7M	2,509,065
BROWN ADVISORY INC	$26.8M	2,122,332
CADIAN CAPITAL MANAGEMENT, LP	$23.8M	1,887,472
VANGUARD CAPITAL MANAGEMENT LLC	$22.3M	1,764,313
Granahan Investment Management, LLC	$22.0M	1,739,097
Impax Asset Management Group plc	$18.0M	1,425,010
Nuveen, LLC	$16.2M	1,285,511
SILVERCREST ASSET MANAGEMENT GROUP LLC	$15.7M	1,244,584

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put SIBN on your watchlist

Track score changes the day SI-BONE, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is SIBN a good stock to buy?

13F Pro's AI-powered analysis of SI-BONE, Inc. (SIBN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SIBN are available on the SIBN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own SIBN?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SIBN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of SI-BONE, Inc.'s investment landscape.